Altogether, despite the ongoing characterization of unique AML-related TP53 mutations, most TP53 abnormalities appear to confer a worse prognosis for AML patients; disease-modifying therapy is clearly needed for this patient population. The gene discussed is TP53; the disease is acute myeloid leukemia.